Prognostic and Predictive Value of CpG Island Methylator Phenotype in Patients with Locally Advanced Nonmetastatic Sporadic Colorectal Cancer
Figure 1
Disease-free survival analysis according to stage and CIMP status. Patients with CIMP positive tumors had a marginally significant poor DFS than those with CIMP negative tumors with value =0.014 (a). Patients with stage II disease showed better DFS than those with stage III disease with value =0.049 (b). DFS: disease-free survival, CIMP: CpG island methylator phenotype.
